Physician profile
Simi Thomas Abraham
NPI 1912608597
$2,456.68
in general payments reported to CMS, 2019-2025
19 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $590 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.69 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $353.83 | 2024-2025 | Ojjaara |
| Pharmaessentia USA Corporation | $258.75 | 2024-2025 | Besremi |
| Astrazeneca Pharmaceuticals Lp | $246.59 | 2024-2025 | Calquence |
| Incyte Corporation | $190.30 | 2025 | Jakafi, Jakafi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $184.60 | 2025 | |
| Astellas Pharma US INC | $173.84 | 2025 | Cresemba |
| Syndax Pharmaceuticals, INC. | $162.65 | 2025 | |
| Teleflex LLC | $153.98 | 2025 | Arrow |
| Sobi, INC | $122.79 | 2024-2025 | |
| Lilly USA, LLC | $114.81 | 2025 | Jaypirca |
| Taiho Oncology, INC. | $93.76 | 2024-2025 | |
| Abbvie INC. | $89.95 | 2025 | |
| Azurity Pharmaceuticals, INC. | $67.25 | 2024-2025 | Danziten, Vivimusta |
| Takeda Pharmaceuticals U.S.A., INC. | $58.10 | 2025 | Iclusig |
| Merck Sharp & Dohme LLC | $54.23 | 2024-2025 | Keytruda, Welireg |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $52.43 | 2024 | Enhertu |
| Alexion Pharmaceuticals, INC. | $28.05 | 2024 | Ultomiris |
| Blueprint Medicines Corporation | $27.84 | 2025 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $22.93 | 2024 | Opdualag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simi Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.